BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31606267)

  • 1. S.Typhi derived OmpC peptide conjugated with Vi-polysaccharide evokes better immune response than free Vi-polysaccharide in mice.
    Haque S; Sengupta S; Gupta D; Bhan MK; Kumar R; Khan A; Jailkhani B
    Biologicals; 2019 Nov; 62():50-56. PubMed ID: 31606267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM
    Micoli F; Bjarnarson SP; Arcuri M; Aradottir Pind AA; Magnusdottir GJ; Necchi F; Di Benedetto R; Carducci M; Schiavo F; Giannelli C; Pisoni I; Martin LB; Del Giudice G; MacLennan CA; Rappuoli R; Jonsdottir I; Saul A
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24443-24449. PubMed ID: 32900928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi.
    Singh M; Ganguly NK; Kumar L; Vohra H
    Microbiol Immunol; 1999; 43(6):535-42. PubMed ID: 10480549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response of S. Typhi-derived Vi polysaccharide and outer membrane protein a conjugate in mice.
    Haque S; Sengupta S; Khan A; Mukhopadhyay AK; Bhan MK; Kumar R; Jailkhani B
    Pediatr Neonatol; 2023 Sep; 64(5):518-527. PubMed ID: 36868948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vi Capsular Polysaccharide Produced by Recombinant
    Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
    Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgA and IgG1 Specific to Vi Polysaccharide of
    Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD
    Front Immunol; 2019; 10():2582. PubMed ID: 31781100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.
    Wahid R; Pasetti MF; Maciel M; Simon JK; Tacket CO; Levine MM; Sztein MB
    Clin Immunol; 2011 Feb; 138(2):187-200. PubMed ID: 21146460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
    Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
    Ni Y; Springer MJ; Guo J; Finger-Baker I; Wilson JP; Cobb RR; Turner D; Tizard I
    Vaccine; 2017 Dec; 35(51):7121-7126. PubMed ID: 29150208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide.
    Staats HF; Kirwan SM; Whisnant CC; Stephenson JL; Wagener DK; Majumder PP
    Clin Vaccine Immunol; 2010 Mar; 17(3):412-9. PubMed ID: 20107010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
    Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
    N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection in a mouse peritonitis model mediated by iron-regulated outer-membrane protein of Salmonella typhi coupled to its Vi antigen.
    Chibber S; Bhardwaj SB
    J Med Microbiol; 2004 Jul; 53(Pt 7):705-709. PubMed ID: 15184544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
    Szu SC; Klugman KP; Hunt S
    Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salmonella Typhi OmpS1 and OmpS2 porins are potent protective immunogens with adjuvant properties.
    Moreno-Eutimio MA; Tenorio-Calvo A; Pastelin-Palacios R; Perez-Shibayama C; Gil-Cruz C; López-Santiago R; Baeza I; Fernández-Mora M; Bonifaz L; Isibasi A; Calva E; López-Macías C
    Immunology; 2013 Aug; 139(4):459-71. PubMed ID: 23432484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The capsular polysaccharide Vi from Salmonella typhi is a B1b antigen.
    Marshall JL; Flores-Langarica A; Kingsley RA; Hitchcock JR; Ross EA; López-Macías C; Lakey J; Martin LB; Toellner KM; MacLennan CA; MacLennan IC; Henderson IR; Dougan G; Cunningham AF
    J Immunol; 2012 Dec; 189(12):5527-32. PubMed ID: 23162127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice.
    Fiorino F; Ciabattini A; Rondini S; Pozzi G; Martin LB; Medaglini D
    Vaccine; 2012 Sep; 30(43):6111-4. PubMed ID: 22705173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles.
    Meena J; Kumar R; Singh M; Ahmed A; Panda AK
    Eur J Pharm Biopharm; 2020 Jul; 152():270-281. PubMed ID: 32470636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates.
    Honda-Okubo Y; Cartee RT; Thanawastien A; Seung Yang J; Killeen KP; Petrovsky N
    Vaccine; 2022 Jul; 40(32):4625-4634. PubMed ID: 35750538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.